Skip to main content
SpringerLink
Log in

Capitalizing on Chemogenomic Concepts

Preclinical Safety Analysis to Help Develop Drugs, Not ‘Duds’

  • Feature Article
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The FDA’s new pharmacogenomics guidance is available at http://www.fda.gov/cder/genomics/default.htm. The website includes detailed information on submitting genomic data, including a decision tree to simplify data submissions, relevant regulatory information, and FDA contact information.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Capitalizing on Chemogenomic Concepts. Pharmaceutical & Diagnostic Innovation 3, 3–7 (2005). https://doi.org/10.1007/BF03256961

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256961

Keywords

Search

Navigation